Obesity: A Key Causative Factor in Cardiovascular Disease Development
Article Sidebar
Main Article Content
Abstract
Abstract
Obesity and cardiovascular diseases have become one of the most pressing public health challenges of the 21st century, garnering widespread attention worldwide. Adipose depot expansion can occur through either an increase in the size of adipocytes (hypertrophy) or the generation of new adipocytes via precursor differentiation during adipogenesis (hyperplasia). Hypertrophy of adipocytes in obesity causes increased hypoxia, triggering fibrosis, inflammation, and necrosis, which contribute to systemic complications, including coronary artery disease, heart failure, and stroke. Furthermore, enlarged adipocytes release pro-inflammatory cytokines like TNF-α and IL-6, driving chronic inflammation that contributes to atherosclerosis, increasing the risk of heart attacks and strokes. We aim to discuss recent insights into the mechanisms by which obesity leads to cardiovascular diseases, which will provide new perspectives for the treatment of obesity and cardiovascular diseases.
Downloads
Article Details
Copyright (c) 2024 Wang S, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Commodore-Mensah Y, Lazo M, Tang O, Echouffo-Tcheugui JB, Ndumele CE, Nambi V, et al. High burden of subclinical and cardiovascular disease risk in adults with metabolically healthy obesity: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2021;44(7):1657-1663. Available from: https://doi.org/10.2337/dc20-2227
Kachur S, Lavie CJ, de Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. Minerva Med. 2017;108(3):212-228. Available from: https://doi.org/10.23736/s0026-4806.17.05022-4
Marfella R, D'Amico M, Di Filippo C, Siniscalchi M, Sasso FC, Ferraraccio F, et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007;6:35. Available from: https://doi.org/10.1186/1475-2840-6-35
Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ. 2021;372:n461. Available from: https://doi.org/10.1136/bmj.n461
Nyawo TA, Pheiffer C, Mazibuko-Mbeje SE, Mthembu SXH, Nyambuya TM, Nkambule BB, et al. Physical exercise potentially targets epicardial adipose tissue to reduce cardiovascular disease risk in patients with metabolic diseases: oxidative stress and inflammation emerge as major therapeutic targets. Antioxidants (Basel). 2021;10(11):1758. Available from: https://doi.org/10.3390/antiox10111758
Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf). 2011;203(3):279-286. Available from: https://doi.org/10.1111/j.1748-1716.2011.02290.x
Francisco V, Ruiz-Fernández C, Pino J, Mera A, González-Gay MA, Gómez R, et al. Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol. 2019;165:196-206. Available from: https://doi.org/10.1016/j.bcp.2019.03.030
Pannu S, Rosmarin D. Psoriasis in patients with metabolic syndrome or type 2 diabetes mellitus: treatment challenges. Am J Clin Dermatol. 2021;22(3):293-300. Available from: https://doi.org/10.1007/s40257-021-00590-y
Lambert EA, Straznicky NE, Dixon JB, Lambert GW. Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity? Am J Physiol Heart Circ Physiol. 2015;309(3):H244-258. Available from: https://doi.org/10.1152/ajpheart.00096.2015
Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal. 2011;15(7):1911-1926. Available from: https://doi.org/10.1089/ars.2010.3739
Evans LE, Taylor JL, Smith CJ, Pritchard HAT, Greenstein AS, Allan SM. Cardiovascular comorbidities, inflammation, and cerebral small vessel disease. Cardiovasc Res. 2021;117(13):2575-2588. Available from: https://doi.org/10.1093/cvr/cvab284
Ząbczyk M, Ariëns RAS, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res. 2023;119(1):94-111. Available from: https://doi.org/10.1093/cvr/cvad017
Bishop NC, Wadley AJ, Hamrouni M, Roberts MJ. Inactivity and obesity: consequences for macrophage-mediated inflammation and the development of cardiometabolic disease. Proceedings of the Nutrition Society. 2023;82:13-21. Available from: https://doi.org/10.1017/s0029665122002671
Wärnberg J, Cunningham K, Romeo J, Marcos A. Physical activity, exercise and low-grade systemic inflammation. Proceedings of the Nutrition Society. 2010;69(4):400-406. Available from: https://doi.org/10.1017/s0029665110001928
Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction. J Nephrol. 2007;20(1):10-14. Available from: https://pubmed.ncbi.nlm.nih.gov/17347967/
Yang J, Zhang LJ, Wang F, Hong T, Liu Z. Molecular imaging of diabetes and diabetic complications: beyond pancreatic β-cell targeting. Adv Drug Deliv Rev. 2019;139:32-50. Available from: https://doi.org/10.1016/j.addr.2018.11.007
Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120(1 Suppl):S12-18. Available from: https://doi.org/10.1016/j.amjmed.2007.01.003
Liu J, Shen W, Zhao B, Wang Y, Wertz K, Weber P, et al. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv Drug Deliv Rev. 2009;61(13):1343-1352. Available from: https://doi.org/10.1016/j.addr.2009.06.007
Li R, Lau WB, Ma XL. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol Sin. 2010;31(10):1258-1266. Available from: https://doi.org/10.1038/aps.2010.95
Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Chayama K, Oshima T. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens. 2001;14(10):1038-1045. Available from: https://doi.org/10.1016/s0895-7061(01)02191-4
Wang S, Wang Y, Lai X, Sun J, Hu M, Chen M, et al. Minimalist nanocomplex with dual regulation of endothelial function and inflammation for targeted therapy of inflammatory vascular diseases. ACS Nano. 2023;17(3):2761-2781. Available from: https://doi.org/10.1021/acsnano.2c11058
Li J, Wang W, Han L, Feng M, Lu H, Yang L, et al. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model. Acta Biochim Biophys Sin (Shanghai). 2017;49(2):149-158. Available from: https://doi.org/10.1093/abbs/gmw128
Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009-1023. Available from: https://doi.org/10.1093/cvr/cvx108
Jiang Q, Liu H, Wang S, Wang J, Tang Y, He Z, et al. Circadian locomotor output cycles kaput accelerates atherosclerotic plaque formation by upregulating plasminogen activator inhibitor-1 expression. Acta Biochim Biophys Sin (Shanghai). 2018;50(9):869-879. Available from: https://doi.org/10.1093/abbs/gmy087
Ren K, Xu XD, Yu XH, Li MQ, Shi MW, Liu QX, et al. LncRNA-modulated autophagy in plaque cells: a new paradigm of gene regulation in atherosclerosis? Aging (Albany NY). 2020;12(21):22335-22349. Available from: https://doi.org/10.18632/aging.103786
Wrońska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf). 2012;205(2):194-208. Available from: https://doi.org/10.1111/j.1748-1716.2012.02409.x
Sirota P, Hadi E, Djaldetti M, Bessler H. Difference in inflammatory cytokine production by mononuclear cells from obese and non-obese schizophrenic patients. Acta Psychiatr Scand. 2015;132(4):301-305. Available from: https://doi.org/10.1111/acps.12396
Ho PY, Chou YC, Koh YC, Lin WS, Chen WJ, Tseng AL, et al. Lactobacillus rhamnosus 069 and Lactobacillus brevis 031: unraveling strain-specific pathways for modulating lipid metabolism and attenuating high-fat-diet-induced obesity in mice. ACS Omega. 2024;9(26):28520-28533. Available from: https://doi.org/10.1021/acsomega.4c02514
Mahadik SR, Lele RD, Saranath D, Seth A, Parikh V. Uncoupling protein-2 (UCP2) gene expression in subcutaneous and omental adipose tissue of Asian Indians: relationship to adiponectin and parameters of metabolic syndrome. Adipocyte. 2012;1(2):101-107. Available from: https://doi.org/10.4161/adip.19671
Biswas SK, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization and plasticity in health and disease. Immunol Res. 2012;53(1-3):11-24. Available from: https://doi.org/10.1007/s12026-012-8291-9
Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther. 2005;22 Suppl 2:3-10. Available from: https://doi.org/10.1111/j.1365-2036.2005.02587.x
Vecchié A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6-17. Available from: https://doi.org/10.1016/j.ejim.2017.10.020
Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, et al. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother. 2024;178:117177. Available from: https://doi.org/10.1016/j.biopha.2024.117177
Webster JD, Vucic D. The balance of TNF-mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues. Front Cell Dev Biol. 2020;8:365. Available from: https://doi.org/10.3389/fcell.2020.00365
Brasier AR. The nuclear factor-kappaB-interleukin-6 signaling pathway mediating vascular inflammation. Cardiovasc Res. 2010;86(2):211-218. Available from: https://doi.org/10.1093/cvr/cvq076
Feijóo-Bandín S, Aragón-Herrera A, Moraña-Fernández S, Anido-Varela L, Tarazón E, Roselló-Lletí E, Portolés M, et al. Adipokines and inflammation: Focus on cardiovascular diseases. Int J Mol Sci. 2020;21(20):7711. Available from: https://doi.org/10.3390/ijms21207711
Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019;56:100980. Available from: https://doi.org/10.1016/j.arr.2019.100980
Tian XY, Ganeshan K, Hong C, Nguyen KD, Qiu Y, Kim J, et al. Thermoneutral housing accelerates metabolic inflammation to potentiate atherosclerosis but not insulin resistance. Cell Metab. 2016;23(1):165-178. Available from: https://doi.org/10.1016/j.cmet.2015.10.003
Saxton SN, Ryding KE, Aldous RG, Withers SB, Ohanian J, Heagerty AM. Role of sympathetic nerves and adipocyte catecholamine uptake in the vasorelaxant function of perivascular adipose tissue. Arterioscler Thromb Vasc Biol. 2018;38(4):880-891. Available from: https://doi.org/10.1161/atvbaha.118.310777
Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108(6):736-740. Available from: https://doi.org/10.1161/01.cir.0000084503.91330.49
Schinzari F, Tesauro M, Rovella V, Di Daniele N, Mores N, Veneziani A, et al. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. J Clin Endocrinol Metab. 2013;98(3):1235-1241. Available from: https://doi.org/10.1210/jc.2012-3424
Nosrati-Oskouie M, Aghili-Moghaddam NS, Sathyapalan T, Sahebkar A. Impact of curcumin on fatty acid metabolism. Phytother Res. 2021;35(9):4748-4762. Available from: https://doi.org/10.1002/ptr.7105
Lee-Rueckert M, Canyelles M, Tondo M, Rotllan N, Kovanen PT, Llorente-Cortes V, et al. Obesity-induced changes in cancer cells and their microenvironment: mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. Semin Cancer Biol. 2023;93:36-51. Available from: https://doi.org/10.1016/j.semcancer.2023.05.002
Perna S, Rafique A, Rondanelli M, Allehdan S, Riso P, Marino M. Effect of caper fruit (Capparis spinosa L.) consumption on liver enzymes, lipid profile, fasting plasma glucose, and weight loss. A systematic review and a preliminary meta-analysis of randomized controlled trials. Biomed Pharmacother. 2023;168:115638. Available from: https://doi.org/10.1016/j.biopha.2023.115638
Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Shabani-Borujeni M, Modaresi S, et al. The effects of vitamin D supplementation on anthropometric and biochemical indices in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Pharmacol. 2021;12:732496. Available from: https://doi.org/10.3389/fphar.2021.732496
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(11):1135-1143. Available from: https://doi.org/10.1161/hc0902.104353
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692-702. Available from: https://doi.org/10.1161/circresaha.115.306361
Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7852):524-533. Available from: https://doi.org/10.1038/s41586-021-03392-8
Liu L, Lan X, Chen X, Dai S, Wang Z, Zhao A, et al. Multi-functional plant flavonoids regulate pathological microenvironments for vascular stent surface engineering. Acta Biomater. 2023;157:655-669. Available from: https://doi.org/10.1016/j.actbio.2022.11.035
Dussault S, Dhahri W, Desjarlais M, Mathieu R, Rivard A. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation. Atherosclerosis. 2014;237(1):194-199. Available from: https://doi.org/10.1016/j.atherosclerosis.2014.09.008
Liu H, Yin G, Kohlhepp MS, Schumacher F, Hundertmark J, Hassan MIA, Heymann F, et al. Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model. Adv Sci (Weinh). 2024;11(30):e2403516. Available from: https://doi.org/10.1002/advs.202403516
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813-1818. Available from: https://doi.org/10.1161/01.cir.103.13.1813
Messerli FH, Sundgaard-Riise K, Reisin ED, Dreslinski GR, Ventura HO, Oigman W, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med. 1983;99(6):757-761. Available from: https://doi.org/10.7326/0003-4819-99-6-757
Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Curr Hypertens Rep. 2020;22(8):82. Available from: https://doi.org/10.1007/s11906-020-01093-7
Rao A, Pandya V, Whaley-Connell A. Obesity and insulin resistance in resistant hypertension: implications for the kidney. Adv Chronic Kidney Dis. 2015;22(3):211-217. Available from: https://doi.org/10.1053/j.ackd.2014.12.004
Jamerson KA. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis. 2000;36(1 Suppl 1):S24-30. Available from: https://doi.org/10.1053/ajkd.2000.9688
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925-1932. Available from: https://doi.org/10.1016/j.jacc.2008.12.068